What's Ahead for America's Biopharmaceutical Research Sector in 2012 and Beyond

What's Ahead for America's Biopharmaceutical Research Sector in 2012 and Beyond

01.04.12 | By

For some important perspective on some of challenges and questions we at PhRMA will be focusing on during 2012 and into the future, take a look at PhRMA President John Castellani's contribution to Chain Drug Review's annual "Pharmacy Outlook '12" issue.

Focusing in on the importance of creating new medicines to help improve patient health, Castellani examines what can be done in the United States to preserve, stimulate and grow a vigorous, innovative and economically strong biopharmaceutical research sector.

After surveying policies to consider and steps that can be taken, Castellani concludes:

"We have the science to propel medical care to previously un-fathomable levels of targeted care. The question is: Do we have the collective fortitude and commitment to fully realize this promise or will we cede the advantage to other countries?"

I recommend a look as the policy, economic and, most importantly, health choices we make in America over the next couple of years will do much to answer Castellani's question.

More On PhRMA — powered by PhRMApedia